Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma

SIMPLE SUMMARY: The development of targeted therapies has led to personalized medicine for advanced non-small cell lung cancer (NSCLC), particularly in lung adenocarcinoma (ADC) with actionable genetic alterations, such as EGFR, ALK, KRAS, and ROS1. Tyrosine kinase inhibitors (TKIs) and angiogenesis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwok, Hoi-Hin, Yang, Jiashuang, Lam, David Chi-Leung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216227/
https://www.ncbi.nlm.nih.gov/pubmed/37345086
http://dx.doi.org/10.3390/cancers15102749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216227/
https://www.ncbi.nlm.nih.gov/pubmed/37345086
http://dx.doi.org/10.3390/cancers15102749

Ejemplares similares